
Browsing restrictions can be lifted for a fee.
-2.17%
Seastar medical holding corporation
0.05%
Avg of Sector
-0.31%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Seastar medical holding corporation (ICU) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ICU's short-term business performance and financial health. For the latest updates on ICU's earnings releases, visit this page regularly.
According to the latest financial report, Seastar medical holding corporation (ICU) reported an Operating Profit of -3.58M with an Operating Margin of -1,955.74% this period, representing a growth of 19.68% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Seastar medical holding corporation (ICU) announced revenue of 183K, with a Year-Over-Year growth rate of 169.12%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, Seastar medical holding corporation (ICU) held Total Cash and Cash Equivalents of 13.76M, accounting for 0.89 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Seastar medical holding corporation (ICU) did not achieve the “three margins increasing” benchmark, with a gross margin of 92.3%%, operating margin of -1,955.74%%, and net margin of -1,897.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ICU's profit trajectory and future growth potential.
According to the past four quarterly reports, Seastar medical holding corporation (ICU)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.13. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Seastar medical holding corporation (ICU)'s Free Cash Flow (FCF) for the period is -3.84M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 23.15% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
The latest valuation data shows Seastar medical holding corporation (ICU) has a Price-To-Earnings (PE) ratio of -1.21 and a Price/Earnings-To-Growth (PEG) ratio of 0.04. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.